Research is ongoing to identify targeted treatment options for individuals with cancer. Progress in understanding the genetic pathway of tumor development has already led to advancements in targeted therapy. The genetic targets could be based on sporadic mutations detected in the tumor, such as EGFR mutations in lung cancer, or inherited germline mutations.
Lynparza (olaparib) is a new treatment option for women with ovarian cancer, and a BRCA1 or BRCA2 Lynparza is a PARP inhibitor that blocks the DNA damage repair pathway associated with these genes. FDA approval for Lynparza is accompanied by specific criteria. A woman must undergo three lines of chemotherapy prior to receiving the drug and have a BRCA1 or BRCA2 mutation.
As research continues to move forward, new clinical trials and ultimately recommendations will become available to improve the treatment of our oncology patients.